FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082807029> ?p ?o ?g. }

• W2082807029 endingPage "140" @default.
• W2082807029 startingPage "135" @default.
• W2082807029 abstract "Glucosamine-6-phosphate synthase (GlmS) catalyzes the formation of d-glucosamine 6-phosphate fromd-fructose 6-phosphate using l-glutamine as the ammonia source. Because N-acetylglucosamine is an essential building block of both bacterial cell walls and fungal cell wall chitin, the enzyme is a potential target for antibacterial and antifungal agents. The most potent carbohydrate-based inhibitor of GlmS reported to date is 2-amino-2-deoxy-d-glucitol 6-phosphate, an analogue of the putative cis-enolamine intermediate formed during catalysis. The interaction of a series of structurally related cis-enolamine intermediate analogues with GlmS is described. Although arabinose oxime 5-phosphate is identified as a good competitive inhibitor of GlmS with an inhibition constant equal to 1.2 (±0.3) mm, the presence of the amino function at the 2-position is shown to be important for potent inhibition. Comparison of the binding affinities of 2-deoxy-d-glucitol 6-phosphate and 2-amino-2-deoxy-d-glucitol 6-phosphate indicates that the amino function contributes −4.1 (±0.1) kcal/mol to the free energy of inhibitor binding. Similarly, comparison of the binding affinities of 2-deoxy-d-glucose 6-phosphate andd-glucosamine 6-phosphate indicates that the amino function contributes −3.0 (±0.1) kcal/mol to the free energy of product binding. Interactions between GlmS and the 2-amino function of its ligands contribute to the uniform binding of the product and thecis-enolamine intermediate as evidenced by the similar contribution of the amino group to the free energy of binding ofd-glucosamine 6-phosphate and 2-amino-2-deoxy-d-glucitol 6-phosphate, respectively. Glucosamine-6-phosphate synthase (GlmS) catalyzes the formation of d-glucosamine 6-phosphate fromd-fructose 6-phosphate using l-glutamine as the ammonia source. Because N-acetylglucosamine is an essential building block of both bacterial cell walls and fungal cell wall chitin, the enzyme is a potential target for antibacterial and antifungal agents. The most potent carbohydrate-based inhibitor of GlmS reported to date is 2-amino-2-deoxy-d-glucitol 6-phosphate, an analogue of the putative cis-enolamine intermediate formed during catalysis. The interaction of a series of structurally related cis-enolamine intermediate analogues with GlmS is described. Although arabinose oxime 5-phosphate is identified as a good competitive inhibitor of GlmS with an inhibition constant equal to 1.2 (±0.3) mm, the presence of the amino function at the 2-position is shown to be important for potent inhibition. Comparison of the binding affinities of 2-deoxy-d-glucitol 6-phosphate and 2-amino-2-deoxy-d-glucitol 6-phosphate indicates that the amino function contributes −4.1 (±0.1) kcal/mol to the free energy of inhibitor binding. Similarly, comparison of the binding affinities of 2-deoxy-d-glucose 6-phosphate andd-glucosamine 6-phosphate indicates that the amino function contributes −3.0 (±0.1) kcal/mol to the free energy of product binding. Interactions between GlmS and the 2-amino function of its ligands contribute to the uniform binding of the product and thecis-enolamine intermediate as evidenced by the similar contribution of the amino group to the free energy of binding ofd-glucosamine 6-phosphate and 2-amino-2-deoxy-d-glucitol 6-phosphate, respectively. glucosamine-6-phosphate synthase d-fructose 6-phosphate d-glucosamine 6-phosphate 2-amino-2-deoxy-d-glucitol 6-phosphate 2-deoxy-d-glucitol 6-phosphate 2-deoxy-d-glucose 6-phosphate Glucosamine-6-phosphate synthase (l-glutamine:d-fructose-6-phosphate aminotransferase (GlmS,1 EC 2.6.1.16)) catalyzes the first step in hexosamine biosynthesis, convertingd-fructose 6-phosphate (Fru-6-P) intod-glucosamine 6-phosphate (GlcN-6-P) using glutamine as the ammonia source (Scheme 1) (1Ghosh S. Blumenthal H.J. Davidson E. Roseman S. J. Biol. Chem. 1960; 235: 1265-1273Abstract Full Text PDF PubMed Google Scholar, 2Badet-Denisot M.-A. René L. Badet B. Bull. Soc. Chim. Fr. 1993; 130: 249-255Google Scholar, 3Massière F. Badet-Denisot M.-A. Cell. Mol. Life Sci. 1998; 54: 205-222Crossref PubMed Scopus (168) Google Scholar). GlcN-6-P is a precursor of uridine diphospho-N-acetylglucosamine from which other amino sugar-containing molecules are derived. One of these products,N-acetylglucosamine, is an important constituent of the peptidoglycan layer of bacterial cell walls and fungal cell wall chitin. Accordingly, GlmS offers a potential target for antibacterial and antifungal agents and has attracted the interest of several research groups (2Badet-Denisot M.-A. René L. Badet B. Bull. Soc. Chim. Fr. 1993; 130: 249-255Google Scholar). GlmS catalyzes two coupled enzymatic reactions. The first is the hydrolysis of glutamine to yield glutamate and nascent ammonia, which is transferred to Fru-6-P. The second reaction is the isomerization of Fru-6-P from a ketose to an aldose, corresponding to a Heyns rearrangement (4Kort M.J. Adv. Carbohydr. Chem. Biochem. 1970; 25: 311-349Crossref Scopus (79) Google Scholar, 5Golinelli-Pimpaneau B. Le Goffic F. Badet B. J. Am. Chem. Soc. 1989; 111: 3029-3034Crossref Scopus (45) Google Scholar). Like other amidotransferases, GlmS is organized into two domains: the NH2-terminal glutamine amidotransferase domain, which catalyzes the hydrolysis of glutamine, and the COOH-terminal synthase domain, which catalyzes the isomerization (3Massière F. Badet-Denisot M.-A. Cell. Mol. Life Sci. 1998; 54: 205-222Crossref PubMed Scopus (168) Google Scholar, 6Mei B. Zalkin H. J. Bacteriol. 1990; 172: 3512-3514Crossref PubMed Google Scholar, 7Zalkin H. Adv. Enzymol. 1993; 66: 203-309PubMed Google Scholar, 8Denisot M.-A. Le Goffic F. Badet B. Arch. Biochem. Biophys. 1991; 288: 225-230Crossref PubMed Scopus (42) Google Scholar). The glutamine hydrolysis reaction has been studied extensively and utilizes the NH2-terminal cysteine thiol, which forms a γ-glutamyl thioester intermediate during the reaction. This catalytic role was confirmed by conversion of the NH2-terminal cysteine to alanine using site-directed mutagenesis which abolished enzymatic activity (2Badet-Denisot M.-A. René L. Badet B. Bull. Soc. Chim. Fr. 1993; 130: 249-255Google Scholar). In general, glutamine amidotransferases are inactivated by glutamine affinity analogues such as 6-diazo-5-oxo-l-norleucine and 6-chloro-5-oxo-l-norleucine (chloroketone), which alkylate the essential cysteine residue (3Massière F. Badet-Denisot M.-A. Cell. Mol. Life Sci. 1998; 54: 205-222Crossref PubMed Scopus (168) Google Scholar, 7Zalkin H. Adv. Enzymol. 1993; 66: 203-309PubMed Google Scholar, 9Buchanan J.M. Adv. Enzymol. 1973; 39: 91-183PubMed Google Scholar). Indeed, many of the active site-directed irreversible inactivators developed for GlmS contain an electrophilic function at the γ-position of glutamate and react irreversibly with the NH2-terminal cysteine residue. More recently, attempts to develop carbohydrate-based inhibitors have been made with the hope of developing more specificity (10Corizzi V. Badet B. Badet-Denisot M.-A. J. Chem. Soc. Chem. Commun. 1992; : 189-190Crossref Google Scholar, 11Badet-Denisot M.-A. Leriche C. Massière F. Badet B. Bioorg. Med. Chem. Lett. 1995; 5: 815-820Crossref Scopus (35) Google Scholar, 12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar, 13Leriche C. Badet-Denisot M.-A. Badet B. Eur. J. Biochem. 1997; 245: 418-422Crossref PubMed Scopus (17) Google Scholar). The ketose/aldose isomerase activity of the enzyme proceeds by abstraction of the C1 pro-R hydrogen of a putative fructosimine 6-phosphate intermediate to form acis-enolamine reactive intermediate that, upon reprotonation at the Re face of C2, gives rise to GlcN-6-P (Scheme 2) (5Golinelli-Pimpaneau B. Le Goffic F. Badet B. J. Am. Chem. Soc. 1989; 111: 3029-3034Crossref Scopus (45) Google Scholar). In accord with this mechanism, Badet and co-workers (14Leriche C. Badet-Denisot M.-A. Badet B. J. Am. Chem. Soc. 1996; 118: 1797-1798Crossref Scopus (29) Google Scholar) have shown that GlmS, in the absence of glutamine, displays a low phosphoglucoisomerase activity. Analogues of the cis-enolamine reactive intermediate are expected to be potent inhibitors of the enzyme (15Wolfenden R. Acc. Chem. Res. 1972; 5: 10-18Crossref Scopus (546) Google Scholar, 16Wolfenden R. Mol. Cell. Biochem. 1974; 3: 111-207Crossref Scopus (87) Google Scholar, 17Wolfenden R. Annu. Rev. Biophys. Bioeng. 1976; 5: 271-306Crossref PubMed Scopus (381) Google Scholar, 18Wolfenden R. Frick L. Page M.I. Williams A. Enzyme Mechanisms. Royal Society of Chemistry, London1987: 97-122Google Scholar) and indeed, 2-amino-2-deoxy-d-glucitol 6-phosphate (GlcNol-6-P) is the most potent carbohydrate-based inhibitor reported to date (11Badet-Denisot M.-A. Leriche C. Massière F. Badet B. Bioorg. Med. Chem. Lett. 1995; 5: 815-820Crossref Scopus (35) Google Scholar, 12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar). Identification of those structural elements necessary for tight binding is an important part of inhibitor design. This paper describes the inhibition of GlmS by several analogues of the cis-enolamine intermediate in an attempt to probe the structural requirements for potent inhibition of this enzyme. The energetic contribution of the 2-amino group to binding of the product and thecis-enolamine intermediate is determined. d-Arabinose, d-arabinose 5-phosphate, 2-amino-2-deoxy-d-glucose 6-phosphate (d-glucosamine 6-phosphate), 2-deoxy-d-glucose 6-phosphate (dGlc-6-P), d-Fru-6-P, and d-ribose 5-phosphate were purchased from Sigma Chemical Company. All other chemicals were analytical grade and used without further purification. NMR spectra (13C, 31P) were obtained using a Bruker AC 250F spectrometer. Chemical shifts (δ) for 13C and 31P spectra are reported relative to the deuterium lock signal and external H3PO4 (85% w/v in D2O), respectively. Elemental analyses were performed by Canadian Microanalytical Service Ltd., B. C. 2-Deoxy-d-glucitol 6-phosphate (dGlcol-6-P) was synthesized by reduction of 2-deoxy-d-glucose 6-phosphate (dGlc-6-P) with sodium borohydride and purified by ion-exchange chromatography following procedures similar to those outlined for the preparation of GlcNol-6-P (12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar). dGlc-6-P (250 mg, 0.868 mmol) was dissolved in 10 ml of water and cooled on ice for 10 min. Sodium borohydride (0.750 g, 19.83 mmol) was added to the dGlc-6-P solution by small portions over 20 min. During the NaBH4 addition, the solution was stirred vigorously and held on ice. After the addition was complete, the solution was stirred for 1 h at room temperature. Reduction was complete as indicated by the inability of the solution to reduce Fehling's reagent. Undissolved NaBH4 was removed by filtration, and the filtrate was cooled on ice. The remaining NaBH4 was destroyed by dropwise addition of 6 m acetic acid over 30 min until the final pH was approximately 4. The solution (25 ml) was allowed to come to room temperature and stirred for 1 h. This solution was then filtered, and the filtrate was applied to a Dowex 50 (H+ form) column (1.5 × 47 cm) and eluted with water. Fractions containing product were identified by thin layer chromatography on cellulose (99% EtOH, n-BuOH, 0.15m sodium citrate buffer, pH 4.0; 10:1:6 v/v/v) developed with an iron-sulfosalicylic acid spray reagent (19Clark J.M. Switzer R.L. Experimental Biochemistry. 2nd Ed. W. H. Freeman and Co., San Francisco1977: 167Google Scholar) sensitive to phosphates. Fractions testing positive for phosphate were pooled and diluted with 0.50 volume of methanol. The solvent was then removed using rotary evaporation (⩽ 37 °C) and freed of borate by repeated treatment with methanol followed by removal of the methanol and methylborate ester by rotary evaporation. The remaining clear syrup was taken up in 10 ml of water and applied to a Dowex 50 (H+form) column (1.5 × 47 cm) eluted with water. Fractions containing dGlcol-6-P were combined and lyophilized yielding a hygroscopic glassy powder (0.1953 g, 78% yield). 13C NMR (62.896 MHz, D2O) δ 38.00 (s, C2), 61.36 (s, C1), 69.18 (d, J C, P = 4.77 Hz, C6), 69.43 (s, C3), 72.77 (d,J C, P = 7.63 Hz, C5), 75.03 (s, C4); 31P NMR (101.26 MHz, D2O) δ decoupled 1.93 (s) and coupled 1.93 (t, J H, P = 5.72 Hz). The disodium salt was converted to the less hygroscopic monocyclohexylammonium salt using Dowex 50 (cyclohexylammonium form). Elemental analysis was as follows. C18H41O8N2P(345.38)Calculated:C41.73%H8.19%N4.06%P8.97%Found:C40.63%H8.12%N3.79%P8.96%ANALYSIS 1 d-Arabinose oxime was prepared by treating d-arabinose with hydroxylamine as described by Finch and Merchant (20Finch P. Merchant Z. Carbohydr. Res. 1979; 76: 225-232Crossref PubMed Scopus (5) Google Scholar, 21Finch P. Merchant Z. J. Chem. Soc. Perkin Trans. I. 1975; : 1682-1686Crossref Scopus (52) Google Scholar) and Hockett et al. (22Hockett R.C. J. Am. Chem. Soc. 1935; 57: 2265-2268Crossref Scopus (9) Google Scholar, 23Hockett R.C. Maynard C.W. J. Am. Chem. Soc. 1939; 61: 2111-2115Crossref Scopus (11) Google Scholar). The oxime was then converted to its corresponding 5-phosphate using hexokinase-catalyzed phosphorylation as described by Finch and Merchant (20Finch P. Merchant Z. Carbohydr. Res. 1979; 76: 225-232Crossref PubMed Scopus (5) Google Scholar). The proton-coupled 31P NMR spectrum of the enzymatically synthesized and isolated d-arabinose oxime 5-phosphate showed broad triplets centered at 5.74 ppm (J H, P = 7.3 Hz) and 4.90 ppm (J H, P = 4.4 Hz). These signals were assigned to the phosphorus nuclei coupled to H-5a,5b in the E andZ oxime phosphate, respectively, similar to the31P NMR assignments reported by Finch and Merchant (20Finch P. Merchant Z. Carbohydr. Res. 1979; 76: 225-232Crossref PubMed Scopus (5) Google Scholar). There were also five very minor peaks (≤ 7%) present at 3.58, −4.74, −4.92, −9.07, and −9.29 possibly due to contaminating phosphoenolpyruvate or nucleotides. The actual concentration ofd-arabinose oxime 5-phosphate used in the inhibition studies was determined by integration of the 1H NMR spectrum. The well resolved doublets at 7.59 ppm and 6.95 ppm arising from H-1 of the E and Z forms were integrated relative to an internal pyrazine standard. The ratio of E toZ oxime determined using 1H NMR was 85:15, respectively, which is in agreement with the reported ratio of 83:17 (20Finch P. Merchant Z. Carbohydr. Res. 1979; 76: 225-232Crossref PubMed Scopus (5) Google Scholar). GlmS was purified as described earlier (12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar, 24Bearne S.L. Wolfenden R. Biochemistry. 1995; 34: 11515-11520Crossref PubMed Scopus (42) Google Scholar). The specific activity of the final preparation was 0.25 unit/mg of protein. GlcN-6-P was determined using a modified Morgan-Elson procedure, and the validity of the assay was established as described previously (12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar, 24Bearne S.L. Wolfenden R. Biochemistry. 1995; 34: 11515-11520Crossref PubMed Scopus (42) Google Scholar). Inorganic and organic phosphate assays were conducted according to the procedures described by Leloir and Cardini (25Leloir L.F. Cardini C.E. Methods Enzymol. 1957; 3: 840-850Crossref Scopus (219) Google Scholar). Assays were conducted in 0.1m potassium phosphate buffer, pH 7.5, containing 1 mm EDTA. The concentration of inhibitors used in the assays were as follows: d-arabinose 5-phosphate, 4.6, 9.1, and 13.7 mm; d-arabinose oxime 5-phosphate, 3.1, 6.2, and 9.4 mm; d-ribose 5-phosphate, 9.1, 18.2, and 27.3 mm; dGlcol-6-P, 25.0 and 50.0 mm; and dGlc-6-p, 57.2 and 171.7 mm. In addition, the assays contained GlmS (6.7 × 10−3unit/ml), l-glutamine (15 mm), andd-Fru-6-P at concentrations equal to 0.45, 0.89, 1.79, 4.47, and 8.94 mm. GlmS was found to be relatively insensitive to changes in ionic strength, and therefore no attempt was made to correct for changes in ionic strength. Complete Michaelis-Menten plots were constructed at all inhibitor concentrations using the concentrations of d-Fru-6-P given above. Kinetic data were analyzed by nonlinear regression analysis of the Michaelis-Menten plots using the program Enzymekinetics(1990) from Trinity Software. The inhibition constants were determined in triplicate, and the average value is reported. The reported error is the S.D. Much attention has been focused on utilizing glutamine analogues to inhibit GlmS activity with the goal of developing antibacterial and antifungal agents. Typically, these analogues possess an electrophilic function at the γ-position of glutamate, which is believed to react irreversibly with the NH2-terminal cysteine residue located in the glutamine amidotransferase domain. The most effective inactivators have beenN 3-fumaroyl-l-2,3-diaminopropanoate derivatives (26Chmara H. Andruszkiewicz R. Borowski E. Biochim. Biophys. Acta. 1985; 870: 357-366Crossref Scopus (51) Google Scholar, 27Badet B. Vermoote P. Le Goffic F. Biochemistry. 1988; 27: 2282-2287Crossref PubMed Scopus (65) Google Scholar, 28Kucharczyk N. Denisot M.-A. Le Goffic F. Badet B. Biochemistry. 1990; 29: 3668-3676Crossref PubMed Scopus (40) Google Scholar, 29Andruszkiewicz R. Chmara H. Milewski S. Borowski E. Int. J. Peptide Res. 1986; 27: 449-453Crossref PubMed Scopus (39) Google Scholar) and 2-amino-3-((N-halomethyl)amino)propanoate derivatives (30Auvin S. Cochet O. Kucharczyk N. Le Goffic F. Badet B. Bioorg. Chem. 1991; 19: 143-151Crossref Scopus (14) Google Scholar,31Milewski S. Chmara H. Andruszkiewicz R. Borowski E. Biochim. Biophys. Acta. 1992; 1115: 225-229Crossref PubMed Scopus (15) Google Scholar). Although the enzyme is believed to follow an ordered Bi Bi kinetic mechanism (27Badet B. Vermoote P. Le Goffic F. Biochemistry. 1988; 27: 2282-2287Crossref PubMed Scopus (65) Google Scholar), glutamine-like inactivators bind and inactivate GlmS effectively even in the absence of the first substrate Fru-6-P (26Chmara H. Andruszkiewicz R. Borowski E. Biochim. Biophys. Acta. 1985; 870: 357-366Crossref Scopus (51) Google Scholar,27Badet B. Vermoote P. Le Goffic F. Biochemistry. 1988; 27: 2282-2287Crossref PubMed Scopus (65) Google Scholar). Recently, there has been an effort to identify carbohydrate-based inhibitors specific for GlmS (10Corizzi V. Badet B. Badet-Denisot M.-A. J. Chem. Soc. Chem. Commun. 1992; : 189-190Crossref Google Scholar, 11Badet-Denisot M.-A. Leriche C. Massière F. Badet B. Bioorg. Med. Chem. Lett. 1995; 5: 815-820Crossref Scopus (35) Google Scholar, 12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar, 13Leriche C. Badet-Denisot M.-A. Badet B. Eur. J. Biochem. 1997; 245: 418-422Crossref PubMed Scopus (17) Google Scholar). One approach to developing potent enzyme inhibitors is to design compounds that are analogues of either the transition states or reactive intermediates that are formed during catalysis (15Wolfenden R. Acc. Chem. Res. 1972; 5: 10-18Crossref Scopus (546) Google Scholar, 16Wolfenden R. Mol. Cell. Biochem. 1974; 3: 111-207Crossref Scopus (87) Google Scholar, 17Wolfenden R. Annu. Rev. Biophys. Bioeng. 1976; 5: 271-306Crossref PubMed Scopus (381) Google Scholar, 18Wolfenden R. Frick L. Page M.I. Williams A. Enzyme Mechanisms. Royal Society of Chemistry, London1987: 97-122Google Scholar). The mechanisms of phosphorylated sugar isomerases that catalyze the interconversion of an aldose and a ketose have been shown to involve proton abstraction from either substrate to give an enzyme-bound cis-enediol intermediate (32Rose I.A. Adv. Enzymol. Relat. Areas Mol. Biol. 1975; 43: 491-517PubMed Google Scholar, 33Rose I.A. Philos. Trans. R. Soc. Lond-Biol. Sci. 1981; 293: 131-143Crossref PubMed Scopus (43) Google Scholar). Virtually all of these enzymes show activity in the absence of metal ions and have exchange (to solvent) to intramolecular hydrogen transfer ratios greater than 1 (33Rose I.A. Philos. Trans. R. Soc. Lond-Biol. Sci. 1981; 293: 131-143Crossref PubMed Scopus (43) Google Scholar, 34Farber G.K. Glasfeld A. Tiraby G. Ringe D. Petsko G.A. Biochemistry. 1989; 28: 7289-7297Crossref PubMed Scopus (109) Google Scholar). As expected, analogues of thecis-enediol are potent inhibitors of such isomerases (18Wolfenden R. Frick L. Page M.I. Williams A. Enzyme Mechanisms. Royal Society of Chemistry, London1987: 97-122Google Scholar). For example, triose-phosphate isomerase is inhibited by 2-phosphoglycolate and 2-phosphoglycolohydroxamate (35Wolfenden R. Biochemistry. 1970; 9: 3404-3407Crossref PubMed Scopus (47) Google Scholar, 36Collins K.D. J. Biol. Chem. 1974; 249: 136-142Abstract Full Text PDF PubMed Google Scholar), glucose-6-phosphate isomerase is inhibited by 5-phosphoarabinoate (37Chirgwin J.M. Noltmann E.A. J. Biol. Chem. 1975; 250: 7272-7276Abstract Full Text PDF PubMed Google Scholar), and both arabinose-5-phosphate isomerase and ribose-5-phosphate epimerase are inhibited by 4-phosphoerythronate (38Woodruff W.W. Wolfenden R. J. Biol. Chem. 1979; 254: 5866-5867Abstract Full Text PDF PubMed Google Scholar, 39Bigham E.C. Gragg C.E. Hall W.R. Kelsey J.E. Mallory W.R. Richardson D.C. Benedict C. Ray P.H. J. Med. Chem. 1984; 27: 717-726Crossref PubMed Scopus (35) Google Scholar). To the extent that the transition state for the rate-determining step resembles an enediol, these analogues may be considered transition state analogues. A similar mechanism has been described for both glucosamine-6-phosphate deaminase (40Midelfort C.F. Rose I.A. Biochemistry. 1977; 16: 1590-1596Crossref PubMed Scopus (48) Google Scholar) and GlmS (5Golinelli-Pimpaneau B. Le Goffic F. Badet B. J. Am. Chem. Soc. 1989; 111: 3029-3034Crossref Scopus (45) Google Scholar) where proton abstraction from the substrate yields an enzyme-bound cis-enolamine intermediate (Scheme 2). In accord with this mechanism, both the deaminase (40Midelfort C.F. Rose I.A. Biochemistry. 1977; 16: 1590-1596Crossref PubMed Scopus (48) Google Scholar) and the synthase (5Golinelli-Pimpaneau B. Le Goffic F. Badet B. J. Am. Chem. Soc. 1989; 111: 3029-3034Crossref Scopus (45) Google Scholar) have exchange (to solvent) to intramolecular hydrogen transfer ratios greater than 1, similar to the phosphosugar isomerases discussed above. In addition, GlcNol-6-P, an analogue of thecis-enolamine intermediate, is a potent inhibitor of both enzymes (11Badet-Denisot M.-A. Leriche C. Massière F. Badet B. Bioorg. Med. Chem. Lett. 1995; 5: 815-820Crossref Scopus (35) Google Scholar, 12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar, 40Midelfort C.F. Rose I.A. Biochemistry. 1977; 16: 1590-1596Crossref PubMed Scopus (48) Google Scholar). In fact, GlcNol-6-P is the tightest binding reversible carbohydrate-based inhibitor reported for GlmS. The present work describes the inhibition of Escherichia coli GlmS by several analogues of the cis-enolamine intermediate and the energetic contribution that the 2-amino function makes to ligand binding. The structures of several analogues of the putative cis-enolamine intermediate and their corresponding inhibition constants (K i) are shown in Table I. In all cases, the analogues were found to be competitive inhibitors of GlmS activity with respect to Fru-6-P. The values of the inhibition constants should be accurate estimates of the dissociation constants for these inhibitors since theK i value for GlcNol-6-P (19 μm) was shown to be very similar to the dissociation constant of 34 (±7) μm determined for this ligand using protection experiments (12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar). The carbonyl functions present in the open chain forms of arabinose 5-phosphate and ribose 5-phosphate mimic the double bond present in the cis-enolamine. That the enzyme displays a low affinity for both of these compounds relative to GlcNol-6-P indicates that the 2-amino and 1-hydroxyl functions are important for tight binding of GlcNol-6-P. Changing the stereochemistry at C2 causes approximately a 4-fold reduction in the binding of ribose 5-phosphate relative to arabinose 5-phosphate. This observation is not unexpected because enzymes that isomerize carbohydrate substrates generally show such stereochemical discrimination (41Noltmann E.A. Enzymes. 1972; 6: 271-354Crossref Scopus (112) Google Scholar).Table ICompetitive inhibition of GlmS by analogues of the enolamine intermediatea Inhibition constant from Bearne (12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar). This value is similar to the value of the inhibitor dissociation constant (K i = 25 μm) determined independently by Badet-Denisot et al. (11Badet-Denisot M.-A. Leriche C. Massière F. Badet B. Bioorg. Med. Chem. Lett. 1995; 5: 815-820Crossref Scopus (35) Google Scholar).b Arabinose 5-phosphate and ribose 5-phosphate are represented as the straight chain forms to highlight their structural similarity to the cis-enolamine intermediate. The K i values shown are the apparent K i values for the combination of all carbohydrate species present in solution (cyclic, acyclic, free aldehyde, and hydrate forms) as outlined under “Results and Discussion.”c The syn (E) isomer is shown to highlight its structural similarity to the cis-enolamine intermediate; however, the K i value shown is for the equilibrium mixture of anti (Z) (15%) andsyn (E) (85%) isomers.d Inhibition constant at saturating concentration of glutamine from Badet et al. (27Badet B. Vermoote P. Le Goffic F. Biochemistry. 1988; 27: 2282-2287Crossref PubMed Scopus (65) Google Scholar). a Inhibition constant from Bearne (12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar). This value is similar to the value of the inhibitor dissociation constant (K i = 25 μm) determined independently by Badet-Denisot et al. (11Badet-Denisot M.-A. Leriche C. Massière F. Badet B. Bioorg. Med. Chem. Lett. 1995; 5: 815-820Crossref Scopus (35) Google Scholar). b Arabinose 5-phosphate and ribose 5-phosphate are represented as the straight chain forms to highlight their structural similarity to the cis-enolamine intermediate. The K i values shown are the apparent K i values for the combination of all carbohydrate species present in solution (cyclic, acyclic, free aldehyde, and hydrate forms) as outlined under “Results and Discussion.” c The syn (E) isomer is shown to highlight its structural similarity to the cis-enolamine intermediate; however, the K i value shown is for the equilibrium mixture of anti (Z) (15%) andsyn (E) (85%) isomers. d Inhibition constant at saturating concentration of glutamine from Badet et al. (27Badet B. Vermoote P. Le Goffic F. Biochemistry. 1988; 27: 2282-2287Crossref PubMed Scopus (65) Google Scholar). Table I shows both arabinose 5-phosphate and ribose 5-phosphate in their acyclic free carbonyl forms so that their structural similarity to the cis-enolamine intermediate is evident. However, in neutral aqueous solution, the acyclic forms of arabinose 5-phosphate and ribose 5-phosphate only comprise approximately 2.4 and 0.6% of the total concentration of species present, respectively (42Pierce J. Serianni A.S. Barker R. J. Am. Chem. Soc. 1985; 107: 2448-2456Crossref Scopus (75) Google Scholar). Under similar conditions, Fru-6-P exists in the β-furanose (81.1%), α-furanose (16.1%), and free carbonyl (2.2%) forms (42Pierce J. Serianni A.S. Barker R. J. Am. Chem. Soc. 1985; 107: 2448-2456Crossref Scopus (75) Google Scholar). Whether the cyclic or acyclic form of Fru-6-P is the actual substrate for GlmS is not known. Badet-Denisot et al. (2Badet-Denisot M.-A. René L. Badet B. Bull. Soc. Chim. Fr. 1993; 130: 249-255Google Scholar) have argued that there is no need for GlmS to catalyze ring opening because the spontaneous rate of ring opening of Fru-6-P (18–21 s−1; Ref. 42Pierce J. Serianni A.S. Barker R. J. Am. Chem. Soc. 1985; 107: 2448-2456Crossref Scopus (75) Google Scholar) is similar to the catalytic rate (19–23 s−1). However, other phosphosugar isomerases that proceed via an enolization mechanism such as glucose-6-phosphate isomerase (43Salas M. Vinuela E. Sols A. J. Biol. Chem. 1965; 240: 561-568Abstract Full Text PDF PubMed Google Scholar, 44Dyson J.E.D. Noltmann E.A. J. Biol. Chem. 1968; 243: 1401-1414Abstract Full Text PDF PubMed Google Scholar, 45Schray K.J. Benkovic S.J. Benkovic P.A. Rose I.A. J. Biol. Chem. 1973; 248: 2219-2224Abstract Full Text PDF PubMed Google Scholar), mannose-6-phosphate isomerase (46Gracy R.W. Noltmann E.A. J. Biol. Chem. 1968; 243: 5410-5419Abstract Full Text PDF PubMed Google Scholar), and GlcN-6-P deaminase (47Oliva G. Fontes M.R. Garratt R.C. Altamirano M.M. Calcagno M.L. Horjales E. Structure. 1995; 3: 1323-1332Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar), are believed to catalyze ring opening of the cyclic carbohydrate substrate to form the corresponding straight chain species prior to deprotonation. Recently, the crystal structures of complexes of the GlmS Fru-6-P binding domain (8Denisot M.-A. Le Goffic F. Badet B. Arch. Biochem. Biophys. 1991; 288: 225-230Crossref PubMed Scopus (42) Google Scholar) with different ligands have been reported, including Glu-6-P (48Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Polikarpov I. Structure. 1998; 6: 1047-1055Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar), GlcN-6-P (48Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Polikarpov I. Structure. 1998; 6: 1047-1055Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar), and GlcNol-6-P (49Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Protein Sci. 1999; 8: 596-602Crossref PubMed Scopus (77) Google Scholar). Based on these crystal structures, Teplyakov and co-workers (48Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Polikarpov I. Structure. 1998; 6: 1047-1055Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar, 49Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Protein Sci. 1999; 8: 596-602Crossref PubMed Scopus (77) Google Scholar) have proposed that GlmS uses His-504 as a general base to catalyze ring opening of cyclic Fru-6-P. Thus it is possible that GlmS may catalyze the ring opening of arabinose 5-phosphate and ribose 5-phosphate. Arabinose 5-phosphate exists in the α-furanose (57.3%), β-furanose (40.4%), hydrate (2.2%), and free carbonyl (⩽0.2%) forms in neutral aqueous solution (40Midelfort C.F. Rose I.A. Biochemistry. 1977; 16: 1590-1596Crossref PubMed Scopus (48) Google Scholar). If the free aldehyde were the actual inhibitory species, adjustment of the observed inhibition constant to reflect the concentration of free carbonyl present in solution would yield an upper limit for the K i value equal to 17 μm. However, there seems to be no convincing reason to adjust the observed inhibition constant in this manner. Arabinose oxime 5-phosphate is an analogue of thecis-enolamine that contains the double bond and the hydroxyl function but lacks the 2-amino function. GlmS binds this analogue with an apparent inhibition constant equal to 1.2 mm, approximately 7-fold less than the K i value observed for arabinose 5-phosphate. It is important to note that the inhibition mixture tested was an equilibrium mixture containing 15% of theanti (Z) form and 85% of the syn(E) form, the latter being analogous to thecis-enolamine intermediate. Adjusting the apparentK i value to reflect the concentration of theE form present in solution gives a K i value equal to 1.0 mm. The affinity that GlmS displays for the oxime is still 53-fold less than the affinity with which GlmS binds GlcNol-6-P. Is this lack of binding affinity principally due to the missing amino function? Replacement of the hydrogen on C2 of the oxime with an amino group would yield a compound that differs from thecis-enolamine intermediate by only the substitution of a nitrogen at C1. Because the amino function contributes approximately 4.1 kcal/mol to the binding affinity (see below), the expectedK i value for such a compound would be approximately 1.3 μm. This value is approximately 15-fold less than theK i value for GlcNol-6-P and might serve as an estimate of the upper limit for the enzyme's affinity for the actualcis-enolamine intermediate. Corizzi et al. (10Corizzi V. Badet B. Badet-Denisot M.-A. J. Chem. Soc. Chem. Commun. 1992; : 189-190Crossref Google Scholar) have reported that the non-isosteric phosphonate analogue of Fru-6-P is a poor competitive inhibitor of GlmS with respect to Fru-6-P (K i = 2.5 mm). However, the oxime of this compound was reported to have a much higher affinity for the enzyme with a K i value equal to 0.2 mm (10Corizzi V. Badet B. Badet-Denisot M.-A. J. Chem. Soc. Chem. Commun. 1992; : 189-190Crossref Google Scholar), which is slightly less than the inhibition constant observed for arabinose oxime 5-phosphate in the present work. This is unexpected because, unlike the arabinose derived oxime, the oxime of the phosphonate is not isosteric with the putativecis-enolamine intermediate. One explanation for this difference in binding affinities may be that the oxime of the phosphonate exists more predominately in the Z form. Unfortunately, the relative amounts of E and Zforms were not reported for the oxime of the phosphonate. Despite the difference in binding affinities, the inhibitory nature of the oximes reflects their structural similarity to the proposedcis-enolamine intermediate. The interactions between an enzyme and a ligand always involve a substantial number of groups. The general approach to understanding the observed affinity has been to dissect it into the contributions of each group by measuring the change in affinity which results when one of the groups of interest is removed (50Jencks W.P. Proc. Natl. Acad. Sci. U. S. A. 1981; 78: 4046-4050Crossref PubMed Scopus (848) Google Scholar, 51Fersht A.R. Shi J.-P. Knill-Jones J. Lowe D.M. Wilkinson A.J. Blow D.M. Brick P. Carter P. Waye M.M.Y. Winter G. Nature. 1985; 314: 235-238Crossref PubMed Scopus (993) Google Scholar, 52Fersht A. Structure and Mechanism in Protein Science. W. H. Freeman and Co., New York1999: 340-345Google Scholar). This type of analysis may be conducted by removing a group from either the enzyme using site-directed mutagenesis or from the ligand (51Fersht A.R. Shi J.-P. Knill-Jones J. Lowe D.M. Wilkinson A.J. Blow D.M. Brick P. Carter P. Waye M.M.Y. Winter G. Nature. 1985; 314: 235-238Crossref PubMed Scopus (993) Google Scholar, 53Street I.P. Armstrong C.R. Withers S.G. Biochemistry. 1986; 25: 6021-6027Crossref PubMed Scopus (188) Google Scholar). When the latter approach is used, the k cat/K m values observed with the natural substrate and a modified substrate may be compared by calculating the effect of the modification on the free energy of the transition state relative to the ground state. Alternatively, transition state analogue inhibitors may be modified and the subsequent changes in binding affinity interpreted as the contribution of the removed moiety to transition state binding (54Kati W.M. Wolfenden R. Science. 1989; 243: 1591-1593Crossref PubMed Scopus (58) Google Scholar). This latter approach is used in the present work to assess the contribution that the 2-amino function makes to the binding of the product (GlcN-6-P) and the reactive intermediate analogue (GlcNol-6-P). 2-Deoxy-d-glucose 6-phosphate, which differs from GlcN-6-P by the absence of an amino function at the 2-position, is only weakly bound by the enzyme (K i = 46 ± 7 mm). This corresponds to a free energy of binding (ΔG dGlc-6-P) equal to −1.90 ± 0.09 kcal/mol compared with a value of −4.85 kcal/mol observed for the binding free energy of GlcN-6-P (ΔG GlcN-6-P) (27Badet B. Vermoote P. Le Goffic F. Biochemistry. 1988; 27: 2282-2287Crossref PubMed Scopus (65) Google Scholar). 2The free energy of binding (ΔG) is calculated using the equation ΔG =RTlnK i where T = 310.2 K and R is the gas constant. The contribution of the amino function to binding (ΔΔG) is calculated using the equation ΔΔG = −RTln(Ki H/Ki NH2) where Ki H andKi NH2 represent the competitive inhibition constants for ligands lacking and containing the 2-amino function, respectively. Thus the 2-amino function contributes −3.0 ± 0.1 kcal/mol (ΔΔG = ΔG GlcN-6-P − ΔG dGlc-6-P) to the free energy of product binding. Similarly, dGlcol-6-P, which differs from GlcNol-6-P by the absence of an amino function at the 2-position, is also only bound weakly by the enzyme (K i = 15 ± 2 mm). This corresponds to a free energy of binding (ΔG dGlcol-6-P) equal to −2.59 ± 0.08 kcal/mol compared with a value of −6.70 ± 0.02 kcal/mol observed for the binding free energy of GlcNol-6-P (ΔG GlcNol-6-P) (12Bearne S.L. J. Biol. Chem. 1996; 271: 3052-3057PubMed Google Scholar). Thus the 2-amino function contributes −4.1 ± 0.1 kcal/mol (ΔΔG = ΔG GlcNol-6-P − ΔG dGlcol-6-P) to the free energy of reactive intermediate analogue binding. These values are similar to the binding free energies reported for amino functions participating in other protein-ligand interactions. For example, ΔΔG values of −3.4 kcal/mol and −6.7 kcal/mol have been reported for the binding contribution of the amino function on ligands interacting with the enzymes phenylalanyl-tRNA synthetase (55Santi D.V. Danenberg P.V. Biochemistry. 1971; 10: 4813-4820Crossref PubMed Scopus (48) Google Scholar, 56Mulivor R. Rappaport H.P. J. Mol. Biol. 1973; 76: 123-134Crossref PubMed Scopus (23) Google Scholar) and isoleucyl-tRNA synthetase (57Holler E. Rainey P. Orme A. Bennett E.L. Calvin M. Biochemistry. 1973; 12: 1150-1159Crossref PubMed Scopus (41) Google Scholar), respectively. For the aminoglycoside 3′-phosphotransferases, types Ia and IIa, values as large as −6 to −11 kcal/mol have been reported for the energetic contribution of the amino function to the stabilization of transition state species (ΔΔG = −RTln((k cat/K m)H/(k cat/K m)NH2)) (58Roestamadji J. Grapsas I. Mobashery S. J. Am. Chem. Soc. 1995; 117: 11060-11069Crossref Scopus (69) Google Scholar). Thus, the amino function at the 2-position contributes approximately the same amount of binding energy to the binding of the product, GlcN-6-P, as it does to the binding of the reactive intermediate analogue, GlcNol-6-P. The amino function, therefore, contributes to theuniform binding (59Albery W.J. Knowles J.R. Biochemistry. 1976; 15: 5631-5640Crossref PubMed Scopus (592) Google Scholar, 60Albery W.J. Knowles J.R. Angew. Chem. Int. Ed. Engl. 1977; 16: 285-293Crossref PubMed Scopus (146) Google Scholar) of both the product and thecis-enolamine intermediate. Selective stabilization of thecis-enolamine intermediate relative to the ground state must therefore be caused by another binding determinant, likely the hydroxyl function at C1. The structures of enzymes complexed to substrates, products, and transition state or reactive intermediate analogues are often useful in delineating the role of enzyme-ligand interactions in catalysis (61Lolis E. Petsko G.A. Annu. Rev. Biochem. 1990; 59: 597-630Crossref PubMed Scopus (69) Google Scholar). The crystal structures of complexes of the Fru-6-P binding domain of GlmS (8Denisot M.-A. Le Goffic F. Badet B. Arch. Biochem. Biophys. 1991; 288: 225-230Crossref PubMed Scopus (42) Google Scholar) with GlcN-6-P (48Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Polikarpov I. Structure. 1998; 6: 1047-1055Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar) and GlcNol-6-P (49Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Protein Sci. 1999; 8: 596-602Crossref PubMed Scopus (77) Google Scholar) show the interactions between the 2-amino group and the isomerase domain which give rise to the observed uniform binding (Fig. 1). The amino group of GlcN-6-P is hydrogen bonded to the carbonyls of Val-399 and Ala-602, and to a water molecule. The water molecule is also hydrogen bonded to the γ-carboxylate of Glu-488 (48Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Polikarpov I. Structure. 1998; 6: 1047-1055Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar). Removal of the 2-amino function is expected to disrupt these three hydrogen bonds resulting in the loss of 3.0 kcal/mol of binding free energy observed when dGlc-6-P is the ligand. The amino group of GlcNol-6-P is hydrogen bonded to the carbonyl of Val-399 and a water molecule. The water molecule is also hydrogen bonded to the ε-amino group of Lys-603 (49Teplyakov A. Obmolova G. Badet-Denisot M.-A. Badet B. Protein Sci. 1999; 8: 596-602Crossref PubMed Scopus (77) Google Scholar). Removal of the amino function from GlcNol-6-P is expected to disrupt these two hydrogen bonding interactions resulting in the loss of 4.1 kcal/mol of binding energy observed when dGlcol-6-P is the ligand. Therefore, although the specific hydrogen bonding interactions between the amino function and the protein appear to change when going from thecis-enolamine intermediate-enzyme complex to the product-enzyme complex with the concomitant gain of a single hydrogen bond in the product-enzyme complex, the total binding affinity for the amino function remains roughly unchanged. Once the structure of the whole enzyme (glutamine amidotransferase and isomerase domains) is solved, it will be interesting to see if the glutamine amidotransferase domain interacts with the amino function. Thus, the interactions between GlmS and the 2-amino function of its ligands are responsible for the uniform binding of the product and thecis-enolamine intermediate as evidenced by the similar contribution of the amino group to the free energy of binding of GlcN-6-P and GlcNol-6-P, respectively. The amino function contributes significantly to the free energy of binding both the product and the reactive intermediate analogue, indicating that the 2-amino function is an important moiety to be included in the design of carbohydrate-based GlmS inhibitors." @default.
• W2082807029 created "2016-06-24" @default.
• W2082807029 creator A5014155093 @default.
• W2082807029 creator A5054585121 @default.
• W2082807029 date "2000-01-01" @default.
• W2082807029 modified "2023-10-01" @default.
• W2082807029 title "Inhibition of Escherichia coliGlucosamine-6-phosphate Synthase by Reactive Intermediate Analogues" @default.
• W2082807029 cites W1474718299 @default.
• W2082807029 cites W1479334442 @default.
• W2082807029 cites W1506579504 @default.
• W2082807029 cites W1534456190 @default.
• W2082807029 cites W1534735697 @default.
• W2082807029 cites W1542143031 @default.
• W2082807029 cites W1559473810 @default.
• W2082807029 cites W1581256861 @default.
• W2082807029 cites W1589370173 @default.
• W2082807029 cites W1677066881 @default.
• W2082807029 cites W1939483636 @default.
• W2082807029 cites W1964607932 @default.
• W2082807029 cites W1966347760 @default.
• W2082807029 cites W1967008494 @default.
• W2082807029 cites W1969802703 @default.
• W2082807029 cites W1978979732 @default.
• W2082807029 cites W1992915538 @default.
• W2082807029 cites W2000449541 @default.
• W2082807029 cites W2006238256 @default.
• W2082807029 cites W2007272508 @default.
• W2082807029 cites W2007659094 @default.
• W2082807029 cites W2007764485 @default.
• W2082807029 cites W2009827762 @default.
• W2082807029 cites W2010032118 @default.
• W2082807029 cites W2018679270 @default.
• W2082807029 cites W2019674322 @default.
• W2082807029 cites W2026161953 @default.
• W2082807029 cites W2028009710 @default.
• W2082807029 cites W2028253641 @default.
• W2082807029 cites W2035846104 @default.
• W2082807029 cites W2040236994 @default.
• W2082807029 cites W2062865122 @default.
• W2082807029 cites W2067962995 @default.
• W2082807029 cites W2069526310 @default.
• W2082807029 cites W2071101217 @default.
• W2082807029 cites W2074228356 @default.
• W2082807029 cites W2079648563 @default.
• W2082807029 cites W2081609898 @default.
• W2082807029 cites W2082240256 @default.
• W2082807029 cites W2085275193 @default.
• W2082807029 cites W2085744296 @default.
• W2082807029 cites W2091657273 @default.
• W2082807029 cites W2092002806 @default.
• W2082807029 cites W2094173546 @default.
• W2082807029 cites W2100082569 @default.
• W2082807029 cites W2146228523 @default.
• W2082807029 cites W2151799162 @default.
• W2082807029 cites W2155638944 @default.
• W2082807029 cites W2164432167 @default.
• W2082807029 cites W2174251851 @default.
• W2082807029 cites W2235917791 @default.
• W2082807029 cites W2321165676 @default.
• W2082807029 cites W2323507925 @default.
• W2082807029 cites W3118834441 @default.
• W2082807029 doi "https://doi.org/10.1074/jbc.275.1.135" @default.
• W2082807029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10617596" @default.
• W2082807029 hasPublicationYear "2000" @default.
• W2082807029 type Work @default.
• W2082807029 sameAs 2082807029 @default.
• W2082807029 citedByCount "45" @default.
• W2082807029 countsByYear W20828070292013 @default.
• W2082807029 countsByYear W20828070292014 @default.
• W2082807029 countsByYear W20828070292015 @default.
• W2082807029 countsByYear W20828070292016 @default.
• W2082807029 countsByYear W20828070292017 @default.
• W2082807029 countsByYear W20828070292018 @default.
• W2082807029 countsByYear W20828070292019 @default.
• W2082807029 countsByYear W20828070292020 @default.
• W2082807029 countsByYear W20828070292021 @default.
• W2082807029 countsByYear W20828070292022 @default.
• W2082807029 countsByYear W20828070292023 @default.
• W2082807029 crossrefType "journal-article" @default.
• W2082807029 hasAuthorship W2082807029A5014155093 @default.
• W2082807029 hasAuthorship W2082807029A5054585121 @default.
• W2082807029 hasBestOaLocation W20828070291 @default.
• W2082807029 hasConcept C104317684 @default.
• W2082807029 hasConcept C112243037 @default.
• W2082807029 hasConcept C181199279 @default.
• W2082807029 hasConcept C185592680 @default.
• W2082807029 hasConcept C2777132085 @default.
• W2082807029 hasConcept C547475151 @default.
• W2082807029 hasConcept C55493867 @default.
• W2082807029 hasConceptScore W2082807029C104317684 @default.
• W2082807029 hasConceptScore W2082807029C112243037 @default.
• W2082807029 hasConceptScore W2082807029C181199279 @default.
• W2082807029 hasConceptScore W2082807029C185592680 @default.
• W2082807029 hasConceptScore W2082807029C2777132085 @default.
• W2082807029 hasConceptScore W2082807029C547475151 @default.
• W2082807029 hasConceptScore W2082807029C55493867 @default.
• W2082807029 hasIssue "1" @default.
• W2082807029 hasLocation W20828070291 @default.

• next